Modified nanodelivery system and method for enhanced in vivo medical and preclinical imaging

Patent metadata

Field	Value
Publication number	US-11090394-B1
Application number	US-201615226070-A
Country	US
Kind code	B1
Filing date	Aug 2, 2016
Priority date	Mar 27, 2012
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

A lipid-, polymer-, and metal-based system of modified nanostructures of active biomedical and pharmaceutical agents used for in vivo (whole body/organ or tissue-specific) imaging. The modified nanostructure system involves various combinations of excipients (lipids, oils, surfactant, polymers, metals, carbon, nanotubes, etc.) in a formulation that allows a user to: (1) sustain the bioluminescent, fluorescent, or contrast signal for a longer period than conventional systems without repetitive administration (e.g., nanostructure system of luciferin), (2) target specific sites of interest (e.g., organ, tissue, receptors, proteins, etc.) for enhanced imaging of the targeted site (e.g. nanostructure system of XenoLight DIR with CREKA allows imaging of tumor vasculature), and (3) increase bioluminescent, fluorescent, or contrast signal flux.

First claim

What is claimed is:

1. A nanoparticle delivery system for intravenously delivering an active substance or agent to a target within a subject for medical and preclinical imaging, comprising:
at least one nanoparticle carrier comprising about 700 mg of at least one solid phase lipid, about 330 mg of at least one liquid phase lipid or oil, and about 480 μl of at least one surfactant;
wherein the at least one solid phase lipid is selected from the group consisting of propylene glycol palmitostearate, glyceryl palmitostearate, and combinations thereof;
wherein the at least one liquid phase lipid or oil is selected from the group consisting of caprylic/capric triglycerides, medium chain triglycerides, diethylene glycol monoethyl ether and combinations thereof;
wherein the at least one surfactant is selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate and a combination thereof;

a luciferin encapsulated within the at least one nanoparticle carrier;
an active pharmaceutical agent encapsulated within the at least one nanoparticle carrier; and
a target-honing molecule conjugated to a surface of the at least one nanoparticle carrier;
wherein biofluorescence of the luciferin occurs as a steady release for up to about 4 hours after intravenous administration of the nanoparticle delivery system to the subject;
wherein the biofluorescence of the luciferin is detectable in the subject for at least 24 hours after intravenous administration of the nanoparticle delivery system to the subject;
wherein release rate of the luciferin is about 50% at 24 hours after intravenous administration with at least 92% encapsulation efficiency;
wherein the nanoparticle delivery system is less than about 200 nm in size;
wherein the nanoparticle delivery system is formed by hot melt homogenization followed by high pressure homogenization.

2. The nanoparticle delivery system of claim 1 , wherein the at least one liquid phase lipid is the caprylic/capric triglyceride.

3. The nanoparticle delivery system of claim 1 , wherein the pharmaceutical agent is 1,1-bis(3′ indolyl)-1-(p-biphenyl)methane (DIM-C-pPhC 6 H 5 ).

4. The nanoparticle delivery system of claim 1 , wherein the target-honing molecule targets a tumor in the subject.

5. The nanoparticle delivery system of claim 4 , wherein the target-honing molecule is a CREKA peptide.

6. The nanoparticle delivery system of claim 1 , wherein nanoparticle delivery system is generated by the process consisting essentially of:
dissolving the bioimaging agent in an organic solvent to form an organic phase solution;
mixing the at least one solid phase lipid and the at least one liquid phase lipid to form a lipid solution;
mixing the organic phase solution with the lipid solution to form a lipid phase solution;
heating the lipid phase solution to remove the organic solvent;
mixing water and a surfactant to form an aqueous phase solution;
mixing the lipid phase solution with the aqueous phase solution to form a mixture;
performing high pressure homogenization on the mixture wherein the at least one nanoparticle carrier encapsulating the bioimaging agent is generated; and
conjugating the target-honing agent to the surface of the at least one nanoparticle carrier.

7. The nanoparticle delivery system of claim 1 , further comprising a nickel chelating compound used as a spacer to conjugate the target-honing molecule.

8. A nanoparticle delivery system for intravenously delivering an active substance or agent to a target within a subject for medical and preclinical imaging, consisting essentially of:
at least one nanoparticle carrier comprising about 700 mg of a solid phase lipid, about 330 mg of a liquid phase lipid or oil, and about 480 μl of at least one surfactant;
wherein the solid phase lipid is propylene glycol palmitostearate;
wherein the liquid phase lipid or oil is a caprylic/capric triglyceride;
wherein the at least one surfactant is selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate and a combination thereof;

a luciferin encapsulated within the at least one nanoparticle carrier;
a target-honing molecule conjugated to a surface of the at least one nanoparticle carrier; and
a nickel chelating compound used as a spacer to conjugate the target-honing molecule;
wherein biofluorescence of the luciferin occurs as a steady release for up to about 4 hours after intravenous administration of the nanoparticle delivery system to the subject;
wherein the biofluorescence of the luciferin is detectable in the subject for at least 24 hours after intravenous administration of the nanoparticle delivery system to the subject;
wherein release rate of the luciferin is about 50% at 24 hours after intravenous administration with at least 92% encapsulation efficiency;
wherein the nanoparticle delivery system is less than 200 nm in size;
wherein the nanoparticle delivery system is formed by hot melt homogenization followed by high pressure homogenization.

Assignees

• Florida A&M Univ

Inventors

• Sachdeva Mandip
• Patel Apurva

Classifications

• A61K49/0093

  Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title

• A61K49/0078

  microemulsion, nanoemulsion · CPC title

• A61K49/0021

  the fluorescent group being a small organic molecule · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K9/1272 Primary

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title